Affliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311201, China.
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China.
Sci Rep. 2023 Nov 22;13(1):20426. doi: 10.1038/s41598-023-47434-9.
This study aimed to assess the expression levels of non-coding RNA activated by DNA damage (NORAD) in the cells, tissues, and serum of breast cancer (BRCA) patients and benign breast nodules and investigate its association with clinicopathological characteristics and prognosis in BRCA. NORAD was analyzed using TCGA-BRCA, GSE77308, Cellminer, and Sangerbox databases, revealing its significance in BRCA prognosis, immune microenvironment, and cell function. Serum samples from 38 BRCA patients, 80 patients with benign breast nodules (50 fibroadenoma and 30 breast adenosis cases), and 42 healthy individuals were collected from Zhejiang Xiaoshan Hospital. NORAD expression was quantified using quantitative reverse transcription PCR (RT-qPCR). Differential NORAD expression between benign and malignant breast nodules and its relationship to clinicopathological characteristics were assessed. NORAD demonstrated elevated expression in BRCA patient serum compared to healthy individuals and those with benign breast nodules (P < 0.05). Moreover, its expression correlated with TNM-stage, lymph node metastasis, and luminal classification. These findings highlight the elevated NORAD expression in BRCA patient serum and its correlation with clinicopathological characteristics, providing insights into its potential as a diagnostic biomarker or therapeutic target.
本研究旨在评估 DNA 损伤激活的非编码 RNA（NORAD）在乳腺癌（BRCA）患者的细胞、组织和血清中的表达水平，并探讨其与 BRCA 临床病理特征和预后的关系。使用 TCGA-BRCA、GSE77308、Cellminer 和 Sangerbox 数据库分析 NORAD，揭示其在 BRCA 预后、免疫微环境和细胞功能中的意义。从浙江萧山医院采集了 38 名 BRCA 患者、80 名良性乳腺结节患者（50 例纤维腺瘤和 30 例乳腺腺病）和 42 名健康个体的血清样本。使用定量逆转录聚合酶链反应（RT-qPCR）定量 NORAD 表达。评估良性和恶性乳腺结节之间的 NORAD 表达差异及其与临床病理特征的关系。NORAD 在 BRCA 患者血清中的表达水平高于健康个体和良性乳腺结节患者（P<0.05）。此外，其表达与 TNM 分期、淋巴结转移和腔型分类相关。这些发现强调了 BRCA 患者血清中 NORAD 表达的升高及其与临床病理特征的相关性，为其作为诊断生物标志物或治疗靶点的潜力提供了依据。
